Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

AP News

AstraZeneca buys Link's neurodegenerative drugs

NEW YORK (AP) — British drugmaker AstraZeneca PLC said Thursday it is buying experimental treatments that show promise for being developed to treat neurodegenerative diseases like Parkinson's disease and Alzheimer's disease from Link Medicine Corp. of Massachusetts.

AstraZeneca did not disclose terms of the deal.

The company said Link Medicine's drug candidates are designed to affect autophagy, a process in which cellular proteins that have been improperly folded are cleared and recycled. Misfolded proteins have been recognized as a cause of some neurodegenerative disorders.

Shares of AstraZeneca fell 50 cents to $45.08 in afternoon trading.

blog comments powered by Disqus